These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 23525615

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS.
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [Abstract] [Full Text] [Related]

  • 3. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW, Vondracek TG.
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [Abstract] [Full Text] [Related]

  • 4. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S, Allison TA, Sharaf S, Yau G, Ranjbar G, Mckaig N, Nguyen A, Escobar M, Choi HA.
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [Abstract] [Full Text] [Related]

  • 5. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S, Uriel N, Yarmohammadi H, Holley CT, Feng A, Roy SS, Reding MT, John R, Eckman P, Zantek ND.
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL.
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [Abstract] [Full Text] [Related]

  • 9. Clinical use of unfractionated heparin therapy in children: time for change?
    Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P.
    Br J Haematol; 2010 Sep; 150(6):674-8. PubMed ID: 20629660
    [Abstract] [Full Text] [Related]

  • 10. The PiCT® test is a reliable alternative to the activated partial thromboplastin time in unfractionated heparin therapy management: results from a multicenter study.
    Brisset AC, Ferrández A, Krause M, Rathbun S, Marlar R, Korte W.
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA, Clement B, Gausman J.
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [Abstract] [Full Text] [Related]

  • 14. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P, Boutière B, Horellou MH, Trzeciak MC, Samama MM.
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM, Anthes AM, Providence SM, Zhao X, Aspinall SL.
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [Abstract] [Full Text] [Related]

  • 16. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
    Adatya S, Sunny R, Fitzpatrick MJ, Colvin M, Thennapan T, John R, Dodge Zantek N, Pritzker M, Eckman P, Uriel N.
    J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
    [Abstract] [Full Text] [Related]

  • 17. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS, Menon V, Schappert J, Wilentz JR, Singh V, Hochman JS.
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [Abstract] [Full Text] [Related]

  • 18. Should we abandon the APTT for monitoring unfractionated heparin?
    Arachchillage DRJ, Kamani F, Deplano S, Banya W, Laffan M.
    Thromb Res; 2017 Sep; 157():157-161. PubMed ID: 28759760
    [Abstract] [Full Text] [Related]

  • 19. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD, Young E, Johnston MA, Robertson C, Naguit I, Stevens P, Galashan D, Oskamp ML, Brennan B, Ginsberg JS.
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.